Refractory Cutaneous Lymphoid Hyperplasia Treated with Rituximab: A Case Report and Literature Review
Keywords:
Cutaneous Lymphoid Hyperplasia, Reactive B-Cell-Rich Lymphoid Proliferations, Pseudolymphoma, Refractory, RituximabAbstract
Cutaneous lymphoid hyperplasia (CLH), recognized as reactive B-cell-rich lymphoid proliferations in the 5th edition of the World Health Organization Classification of Haematolymphoid Tumours, is a benign reactive inflammatory condition that clinically and histologically resembles cutaneous lymphoma and can present with a predominance of B-cells, T-cells, or a mixture of both. The majority of patients present with a single papule, nodule, or plaque. Nevertheless, numerous or extensive lesions can rarely develop. We report a case of CLH with multiple nodules and plaques on the face. The patient had a progressive refractory disease and showed poor response to numerous therapies, including topical, intralesional, and systemic corticosteroids, topical calcineurin inhibitors, doxycycline, isotretinoin, hydroxychloroquine, and methotrexate, but showed a great response to rituximab, a monoclonal antibody targeted against the CD20 antigen.
References
Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, Araujo IBO, Berti E, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia 2022;36:1720-48.
Khalil S, Donthi D, Gru AA. Cutaneous reactive B-cell lymphoid proliferations. J Cutan Pathol 2022;49:898-916.
Miguel D, Peckruhn M, Elsner P. Treatment of Cutaneous Pseudolymphoma: A Systematic Review. Acta Derm Venereol 2018;98:310-7.
Besch-Stokes JG, Patel MH, Brumfiel CM, Costello CM, Rule W, Rosenthal A, et al. Cutaneous B cell pseudolymphoma treated with rituximab and methotrexate. Dermatol Online J 2021;27.
Joshi TP, Duvic M, Torres-Cabala CA, Tschen J. Treatment With Dupilumab for Refractory Cutaneous B-Cell Pseudolymphoma. JAMA Dermatol 2022;158:697-9.
Mitteldorf C, Kempf W. Cutaneous pseudolymphoma-A review on the spectrum and a proposal for a new classification. J Cutan Pathol 2020;47:76-97.
García-Rodiño S, Espasandín-Arias M, Suárez-Peñaranda JM, Rodríguez-Granados MT, Vázquez-Veiga H, Fernández-Redondo V. Persisting allergic patch test reaction to minoxidil manifested as cutaneous lymphoid hyperplasia. Contact Dermatitis 2015;72:413-6.
Singh N, Fagan KK, Patel RT, Grider DJ. Pseudolymphoma to Lymphoma: A Case of Chronic Reactive Lymphoid Hyperplasia Transforming to Primary Cutaneous Marginal Zone Lymphoma. Am J Dermatopathol 2023;45:250-3.
Witzig TE, Inwards DJ, Habermann TM, Dogan A, Kurtin PJ, Gross JB, Jr., et al. Treatment of benign orbital pseudolymphomas with the monoclonal anti-CD20 antibody rituximab. Mayo Clin Proc 2007;82:692-9.
Behrouz Sharif S, Neilagh A, Barenji M. Cutaneous Pseudolymphoma: A Brief Review and Report of a Case Treatment Using Rituximab. Annals of Pathology and Laboratory Medicine 2019;6.
Balode D, Beļajeva L, Ruesseler V, Quaas A, Lejniece S. Diagnostic Challenges and Treatment Options for Cutaneous T Cell Pseudolymphoma: A Case Study with Rituximab Treatment. Am J Case Rep 2020;21:e919616.
Martin SJ, Duvic M. Treatment of cutaneous lymphoid hyperplasia with the monoclonal anti-CD20 antibody rituximab. Clin Lymphoma Myeloma Leuk 2011;11:286-8.
Matin M, Asilian Mahabadi A, Poor S, Haftbaradaran E, Feily A. Treatment of Cutaneous Lymphoid Hyperplasia with Rituximab: A Case Report of 3 Patients. Dermatology Case Reports 2019;04.
Heelan K, Al-Mohammedi F, Smith MJ, Knowles S, Lansang P, Walsh S, et al. Durable remission of pemphigus with a fixed-dose rituximab protocol. JAMA Dermatol 2014;150:703-8.
Amber KT, Hertl M. An assessment of treatment history and its association with clinical outcomes and relapse in 155 pemphigus patients with response to a single cycle of rituximab. J Eur Acad Dermatol Venereol 2015;29:777-82.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Thai Journal of Dermatology
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
เนื้อหาและข้อมูลในบทความที่ลงตีพิมพ์ในวารสารโรคผิวหนัง ถือเป็นข้อคิดเห็นและความรับผิดชอบของผู้เขียนบทความโดยตรงซึ่งกองบรรณาธิการวารสาร ไม่จำเป็นต้องเห็นด้วย หรือร่วมรับผิดชอบใดๆ
บทความ ข้อมูล เนื้อหา รูปภาพ ฯลฯ ที่ได้รับการตีพิมพ์ในวารสารโรคผิวหนัง ถือเป็นลิขสิทธิ์ของวารสารฯ หากบุคคลหรือหน่วยงานใดต้องการนำทั้งหมดหรือส่วนหนึ่งส่วนใดไปเผยแพร่ต่อหรือเพื่อกระทำการใดๆ จะต้องได้รับอนุญาตเป็นลายลักอักษรจากบรรณาธิการวารสารโรคผิวหนังก่อนเท่านั้น
